Alan F. Denenberg

Davis Polk advised the underwriters in connection with the initial public offering of 30,000,000 units of Prime Impact Acquisition I, for aggregate proceeds of $300 million. Each unit…

Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Globe Life Inc. of $50 million aggregate principal amount of 2.150% senior notes due 2030…

Davis Polk is advising JP Morgan Securities LLC and Lazard as financial advisers to Aimmune Therapeutics in connection with its $2.6 billion sale to Sociétés des Produits Nestlé, S.A., a…

Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Globe Life Inc. of $350 million aggregate principal amount of 2.150% senior notes due…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an SEC-registered offering of common stock by iRhythm Technologies…

Davis Polk advised the financial adviser to Microchip Technology Incorporated in connection with Microchip’s privately negotiated exchanges of $414.3 million aggregate principal amount of…

Davis Polk advised the joint book-running managers in connection with a $575 million SEC-registered debt offering by Flex Ltd. The offering consisted of $250 million aggregate…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $125 million public offering of common stock by Personalis, Inc. The common stock…

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by IDEAYA Biosciences, Inc. of its common stock for up to an aggregate amount of $50 million. Based in…

Davis Polk advised the initial purchaser in connection with a Rule 144A offering by Bloom Energy Corporation of $200 million aggregate principal amount of its 2.500% green convertible…